Modulating cirrhotic-ECM by targeting DDR1 with nilotinib efficiently reverse NETs-dominant immune-suppressive TME, enhancing the aPD-1 treatment in HCC with cirrhosis, presenting an appealing therapeutic prospect. Here, DDR1 is linked to Cirrhosis.